Ryan Beard, MD
Cardiovascular Disease · Winfield, KSNPI 1962658021
Payments from drug & device makers
Across 557 payments — averaging $34.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Abbott$4K
- Penumbra, Inc.$1K
- AstraZeneca$787
- Johnson & Johnson$749
- E.r. Squibb & Sons, L.L.C.$706
- plus $4K from 31 others
What the payments were for
- Travel & lodging$6,41334%
- Food & beverage$12,56666%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 104 | $7,641 |
| Abbott | 82 | $4,235 |
| Penumbra, Inc. | 6 | $1,082 |
| AstraZeneca | 43 | $787 |
| Johnson & Johnson | 53 | $749 |
| E.r. Squibb & Sons, L.L.C. | 59 | $706 |
| Novartis | 48 | $674 |
| Merck | 33 | $576 |
| Boston Scientific | 10 | $528 |
| Biotronik Inc. | 27 | $323 |
| Amgen | 19 | $257 |
| Shockwave Medical, Inc | 4 | $182 |
| Amarin Pharma, Inc. | 9 | $160 |
| Inari Medical, Inc. | 1 | $107 |
| Sanofi-aventis U.S. LLC | 7 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $97 |
| Endologix LLC | 1 | $96 |
| Pfizer | 6 | $80 |
| Boehringer Ingelheim | 4 | $72 |
| Esperion Therapeutics, Inc. | 4 | $69 |
| Bayer | 3 | $61 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $58 |
| Lundbeck LLC | 3 | $55 |
| United Therapeutics Corporation | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Bardy Diagnostics, Inc. | 2 | $37 |
| Gilead | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Surmodics, Inc. | 3 | $23 |
| Edwards Lifesciences | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| My01 Inc. | 1 | $18 |
| Abiomed | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Preventice Services, LLC | 2 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$3,867
- AVEIR$2,162
- Indigo System$860
- Attain$690
- SYMPLICITY G3$163
- ASSURITY$156
- CardioMEMS HF System$126
- CAMZYOS$123
- OPTIS$121
- Watchman$117
- Confirm Rx$112
- Cobalt$112
- MitraClip$110
- WATCHMAN Access System$107
- FLOWTRIEVER CATHETER, S$107
- CT THROMBECTOMY SYSTEM KIT$107
How this compares
$19,031 in reported general payments places this provider in the 85th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 551 | $453,062 |
| XareltoRivaroxaban | 227 | $203,015 |
| CamzyosMavacamten | 18 | $141,469 |
| EntrestoSacubitril/Valsartan | 134 | $116,162 |
| FarxigaDapagliflozin Propanediol | 81 | $50,139 |
| BrilintaTicagrelor | 66 | $45,283 |
| Repatha SureclickEvolocumab | 15 | $23,549 |
| VerquvoVericiguat | 15 | $11,868 |
| JardianceEmpagliflozin | 14 | $11,535 |
| Repatha SyringeEvolocumab | 18 | $9,911 |
| CorlanorIvabradine Hcl | 24 | $7,134 |
| Bumetanide | 249 | $6,405 |
| SotalolSotalol Hcl | 252 | $4,153 |
| Flecainide Acetate | 154 | $3,931 |
| Metoprolol Succinate | 380 | $3,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $453,062551 claims |
| Johnson & JohnsonXarelto | $749 | $203,015227 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $706 | $141,46918 claims |
| NovartisEntresto | $674 | $116,162134 claims |
| AstraZenecaFarxiga, Brilinta | $787 | $95,422147 claims |
| MerckVerquvo | $576 | $11,86815 claims |
| Boehringer IngelheimJardiance | $72 | $11,53514 claims |
| AmgenCorlanor | $257 | $7,13424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Winfield
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Aziz MaksoudWichita$847K
- Stephen BloomOverland Park$766K
- Vasvi SinghOverland Park$436K
- Lloyd StahlOverland Park$275K
- Thomas AshcomWichita$193K
- Chen Hoe ChowTopeka$187K
- Joseph GalichiaWichita$177K
- Mazhar AfaqKansas City$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.